KCC2 Epilepsy Program

About BioSymetrics

BioSymetrics is an AI/ML-enabled drug discovery company tackling the high failure rate in clinical trials by connecting human phenotypic and genotypic data with in vivo validation in model systems. The company's proprietary platform, Elion, uses patented Contingent AI™ and zebrafish phenotypic models to rapidly identify and validate novel therapeutic targets. With a pipeline initially focused on epilepsies and partnerships providing access to massive datasets, BioSymetrics aims to de-risk the early discovery process and deliver more translatable candidates.

Therapeutic Areas